Suscribirse

Fluorodeoxyglucose Positron Emission Tomography Detects Persistent Arterial Inflammation After Symptomatic COVID-19 - 06/09/25

Doi : 10.1016/j.hlc.2025.03.005 
Heidi Espedal, PhD a, Shipra Verma, MD b, Ambuj Roy, MD c, Nick S.R. Lan, MBBS, MClinRes, MSc d, e, f, Sheeraz Mohd, PhD d, Benjamin Bartlett, PhD d, Kamar Ali, MSc c, Natalie C. Ward, PhD g, Martin A. Ebert, PhD h, i, j, k, Dick C. Chan, MD, PhD f, Gerald F. Watts, MD, PhD f, l, Girish Dwivedi, MD, PhD d, e, f, , Roslyn J. Francis, MD, PhD a, f, h, m,
a Western Australia National Imaging Facility, The University of Western Australia, Perth, WA, Australia 
b Department of Nuclear Medicine, Fiona Stanley Hospital, Murdoch, WA, Australia 
c Department of Cardiology, All India Institute of Medical Sciences, New Delhi, India 
d Department of Advanced Clinical and Translational Cardiovascular Imaging, Harry Perkins Institute of Medical Research, Murdoch, WA, Australia 
e Department of Cardiology, South Metropolitan Health Service, Fiona Stanley Fremantle Hospitals Group, Murdoch, WA, Australia 
f Medical School, The University of Western Australia, Perth, WA, Australia 
g Dobney Hypertension Centre, Medical School, The University of Western Australia, Perth, WA, Australia 
h Australian Centre for Quantitative Imaging, Medical School, The University of Western Australia, Perth, WA, Australia 
i School of Physics, Mathematics and Computing, The University of Western Australia, Perth, WA, Australia 
j Department of Radiation Oncology, Sir Charles Gairdner Hospital, Perth, WA, Australia 
k School of Medicine and Public Health, University of Wisconsin, Madison, WI, USA 
l Cardiometabolic Clinic, Department of Cardiology, Royal Perth Hospital, Perth, WA, Australia 
m Nuclear Medicine Department, Sir Charles Gairdner Hospital, Perth, WA, Australia 

Corresponding author at: Department of Advanced Clinical and Translational Cardiovascular Imaging, Harry Perkins Institute of Medical Research, 6 Verdun St, Nedlands, WA 6009, AustraliaDepartment of Advanced Clinical and Translational Cardiovascular ImagingHarry Perkins Institute of Medical Research6 Verdun StNedlandsWA6009Australia∗∗Corresponding author at: Medical School, The University of Western Australia, 6 Verdun St, Nedlands, WA 6009, AustraliaMedical SchoolThe University of Western Australia6 Verdun StNedlandsWA6009Australia

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
Artículo gratuito.

Conéctese para beneficiarse!

Abstract

Background

There is limited knowledge of persisting vascular and systemic inflammation in adults recovered from COVID-19. This study aimed to assess whether inflammation from symptomatic mild-to-moderate COVID-19 persists beyond the apparent clinical resolution of disease using fluorodeoxyglucose positron emission tomography (FDG-PET).

Method

This observational single-centre cohort study invited adults (aged >40 years) who had clinically recovered from mild-to-moderate COVID-19. Whole-body FDG-PET imaging and C-reactive protein test were performed on the same day after a minimum of 30 days after COVID-19 diagnosis. COVID-19–naive adults at high-risk for cardiovascular disease (CVD) were included for comparison (n=8); thoracic FDG-PET imaging was performed for these participants.

Results

FDG-PET imaging was performed after a median of 97 days (interquartile range [IQR] 75–113 days) after COVID-19 diagnosis. Participants who recovered from COVID-19 showed an increased arterial inflammation (median standard uptake value [SUV]max 3.1; IQR 2.7–3.3) compared with the high-risk participants with CVD (median SUVmax 2.5; IQR 2.2–2.8; p<0.001). There was a moderate positive correlation between the total thoracic SUVmax and the bone marrow SUVmean (Spearman r=0.58; p<0.001) and the spleen mean SUVmax (Spearman r=0.62, p<0.001) for participants who recovered from COVID-19.

Conclusions

Ongoing arterial inflammation is detected by FDG-PET imaging after mild-to-moderate COVID-19. Larger prospective studies are needed to assess the implications on CVD risk.

El texto completo de este artículo está disponible en PDF.

Keywords : COVID-19, Vascular inflammation, FDG-PET, Infection


Esquema


© 2025  The Author(s). Publicado por Elsevier Masson SAS. Todos los derechos reservados.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 34 - N° 9

P. 969-976 - septembre 2025 Regresar al número
Artículo precedente Artículo precedente
  • Impact of Deep Sternal Wound Infection on Long-Term Survival Based on Revascularisation Strategy: Results From the Polish National Registry
  • Sleiman Sebastian Aboul-Hassan, Grzegorz Hirnle, Bartlomiej Perek, Marek Jemielity, Szymon Kocanda, Tomasz Hirnle, Miroslaw Brykczynski, Radoslaw Gocol, Marek Deja, Jan Rogowski, Michal Krejca, Wojciech Pawliszak, Kazimierz Widenka, Jerzy Pacholewicz, Pawel Bugajski, Krzysztof Wrobel, Bohdan J. Maruszewski, Tomasz Hrapkowicz, Romuald Cichon, KROK Investigators
| Artículo siguiente Artículo siguiente
  • Eligibility for Semaglutide 2.4 mg in Patients With Acute Myocardial Infarction and Overweight or Obesity Without Diabetes: A Real-World Analysis
  • Rahil Ajmera, Hassan Karim, P. Gerry Fegan, Girish Dwivedi, Nick S.R. Lan

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.

@@150455@@ Voir plus

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2026 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.